Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective

被引：0
|
作者：
Fuming Li
Yingyao Chen
Dunming Xiao
Shan Jiang
Yi Yang
机构：
[1] Fudan University,School of Public Health
[2] National Health Commission Key Laboratory of Health Technology Assessment (Fudan University),Macquarie University Centre for the Health Economy, Macquarie Business School and Australian Institute of Health Innovation
[3] Macquarie University,undefined
来源：
Advances in Therapy | 2024年 / 41卷
关键词：
Non-small cell lung cancer; Costs and cost analysis; Cost-effectiveness analysis; Immunotherapy; Sintilimab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1436 / 1449
页数：13
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective
    Li, Fuming
    Chen, Yingyao
    Xiao, Dunming
    Jiang, Shan
    Yang, Yi
    [J]. ADVANCES IN THERAPY, 2024, 41 (04) : 1436 - 1449
  • [2] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
  • [3] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    [J]. ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
  • [5] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Dong Ding
    Huabin Hu
    Mengting Liao
    Yin Shi
    Longjiang She
    Linli Yao
    Youwen Zhu
    Shan Zeng
    Jin Huang
    [J]. Advances in Therapy, 2020, 37 : 2116 - 2126
  • [6] Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China
    Liu, Huiqin
    Wang, Ying
    He, Qi
    [J]. HEALTH ECONOMICS REVIEW, 2022, 12 (01)
  • [7] Cost-effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    [J]. IMMUNOTHERAPY, 2023, 15 (14) : 1133 - 1142
  • [8] A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer
    Panje, C. M.
    Dedes, K. J.
    Matter-Walstra, K.
    Schwenkglenks, M.
    Gautschi, O.
    Siano, M.
    Aebersold, D. M.
    Plasswilm, L.
    Lupatsch, J. E.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (06) : 588 - 588
  • [9] COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA
    Alhammad, A.
    Lecca, Garrido S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A741 - A741
  • [10] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB VS. PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS, ADVANCED NON-SMALL CELL LUNG CANCER IN THE USA
    Chen, J.
    Velcheti, V.
    Padula, W.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S342 - S342
12345